Please assess the completion status of the following clinical trial:

Trial Title: Advisa MRI Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a Class I or II indication for implantation of a dual chamber pacemaker according to the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) guidelines~* Subjects who are able to undergo a pectoral implant~* Subjects who are able and willing to undergo elective magnetic resonance (MR) scanning without sedation~* Subjects who are geographically stable and available for follow-up at the study center for the length of the study~Exclusion Criteria:~* Subjects with a mechanical tricuspid heart valve~* Subjects with a history of significant tricuspid valvular disease~* Subjects for whom a single dose of 1.0 milligram (mg) dexamethasone acetate may be contraindicated~* Subjects who require a legally authorized representative to obtain consent~* Subjects who have a previously implanted pacemaker or implantable cardioverter defibrillator (ICD) (abandoned pacemaker and/or defibrillator leads are not permitted; however subjects with complete system explants are not excluded)~* Subjects who are immediate candidates for an ICD~* Subjects who require an indicated MR scan, other than those specifically described in the study, before the 4 months follow-up~* Subjects with previously implanted active medical devices~* Subjects with a non-MRI compatible device (such as ICDs or neurostimulators) or material implant (e.g. non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys)~* Subjects with medical conditions that preclude the testing required by the protocol or limit study participation~* Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study~* Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control~* Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI group (Type: EXPERIMENTAL): Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
- Control group (Type: ACTIVE_COMPARATOR): Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).